NeuroKaire develops a clinical test that uses a simple blood draw and patient‑derived neurons to provide a neuronal readout of antidepressant effects, combined with clinical data and a pharmacogenetic screen covering 132 drugs. The test is designed to help clinicians identify the optimal antidepressant for individual patients, reduce trial‑and‑error prescribing, and enable faster, lower‑dose, and safer treatment. NeuroKaire also positions its technology for pharmaceutical and biotechnology partners to bring precision medicine into drug development across psychiatry and neurology. The company said it will use new funding to scale operations, expand its team, deepen research and development, and expand pharmaceutical partnerships focused on multiple psychiatric and neurological diseases. The announcement highlights ongoing efforts to expand pharmaceutical collaborations and to deploy the test in clinical and drug‑development settings. The company is based in Kearny, N.J. Genetika+ builds personalized medicine solutions for psychiatric and neurological diseases using its Brain-in-a-Dish technology. The company’s first indication, NeuroKaire, rapidly tests more than 70 approved antidepressants and combinations against an individual patient’s neurological biomarkers. Genetika+ combines these functional readouts with patients’ genetic and medical history to predict optimal drug or combination therapies, aiming to reduce trial-and-error prescribing, side effects, and time to effective treatment. The platform is positioned to enable faster treatment, lower dosing, and fewer adverse outcomes versus current practice. Several clinical studies are underway and additional trials are planned to further validate the tool. Genetika+ was founded in 2018 by Talia Cohen-Solal and Daphna Laifenfeld and is based in Tel Aviv, Israel.

Total raised

$28M

Funding rounds

2

Latest round

Series A

Latest activity

Dec 2024